Active, Not Recruiting
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
NCT03016871
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Yale University New Haven, Connecticut, United States
- M D Anderson Cancer Center Houston, Texas, United States
- Fred Hutchinson Cancer Research Center Seattle, Washington, United States